Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$122.84 USD

122.84
2,716,497

+0.02 (0.02%)

Updated Jul 12, 2024 01:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Novavax (NVAX) Starts A New Study on COVID-Flu Combo Jab

Novavax (NVAX) initiates a mid-stage study evaluating its COVID-19-Influenza combination and standalone influenza vaccines in adults aged 50 through 80 years.

Moderna (MRNA) Gains As Market Dips: What You Should Know

Moderna (MRNA) closed the most recent trading day at $179.62, moving +0.42% from the previous trading session.

Andrew Rocco headshot

Biotech: 3 Profitable Bios Worth Owning

The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.

Andrew Rocco headshot

Biotech is Set for a Blockbuster 2023: Here's Why

The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?

Stock Market News for Dec 21, 2022

Wall Street closed higher on Tuesday terminating a four-day losing streak.

Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.

Stock Market News for Dec 19, 2022

U.S. stock markets closed sharply lower On Friday as market participants remained concerned about a recession in 2023.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.

Company News for Dec 15, 2022

Companies in The News Are:BRZE,DAL,MRNA,MRK,SOFI

Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study

Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.

Andrew Rocco headshot

Trending Today: 5 Stocks in the News

So far this week, several stocks have had headline-driven catalysts. We will cover 5 stocks trending in the news.

Vertex (VRTX) to Start Clinical Study on mRNA-based CF Therapy

Following clearance of the IND application by the FDA, Vertex (VRTX) intends to start a clinical study evaluating a single ascending dose of VX-522 in cystic fibrosis patients in the coming weeks.

Mark Vickery headshot

Top Stock Reports for JPMorgan, Intel & Advanced Micro Devices

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Intel Corporation (INTC) and Advanced Micro Devices, Inc. (AMD).

Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag

The FDA grants fast-track designation to Pfizer (PFE)/BioNTech's (BNTX) early-stage combination vaccine candidate, which targets two respiratory diseases - influenza and COVID-19.

Indrajit Bandyopadhyay headshot

3 Medical Stocks With Solid Growth Drivers to Keep Track Of

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.

Company News for Dec 9, 2022

Companies in The News Are: COP, NVDA, MRNA, RENT

Company News for Dec 8, 2022

Companies in The News Are: UAL, BKNG, MRNA, CVNA

Andrew Rocco headshot

Bucking the Trend: 3 Stocks Showing Stellar Relative Strength this Week

Market pullbacks can offer a treasure trove of ideas in the form of relative strength.

Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

Shaun Pruitt headshot

Should Investors Buy Pfizer (PFE) & Moderna (MRNA) Stock for 2023?

Much of the social and economic post-pandemic recovery is accredited to Covid-19 vaccine makers Pfizer (PFE) and Moderna (MRNA). Investors may be wondering if these stocks will continue to be strong investments going into 2023.

Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.